Get the latest news, insights, and market updates on CPIX (Cumberland Pharmaceuticals Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Cumberland Pharmaceuticals Q4 Earnings Call Highlights
Cumberland Pharmaceuticals (NASDAQ:CPIX) reported fourth-quarter and full-year 2025 results and provided a business update during its earnings call, highlighting revenue growth across its portfolio, progress in pipeline programs led by ifetroban, and continued expansion into international markets. Mar 3, 2026 - $CPIX
Cumberland: Q4 Earnings Snapshot
CPIX) on Tuesday reported a loss of $1.4 million in its fourth quarter. On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 9 cents. Losses, adjusted for one-time gains and costs, came to 1 cent per share. Mar 3, 2026 - $CPIX
CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourth quarter of 2025, a 31% increase over the prior year period. Mar 3, 2026 - $CPIX
Joint U.S. Commercialization of RedHill's Talicia® Commences
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. ("THI") and Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), has started and is now being rolled out to support accelerated market penetration and expanded reach. This marks the operational launch of the joint commercialization model previously anno Feb 25, 2026 - $CPIX
CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today announced the launch of its national sales promotional for Talicia®. Cumberland has assumed responsibility for the distribution and sales promotion of the brand in the U.S. under the co-commercialization agreement with RedHill Biopharma. Feb 25, 2026 - $CPIX
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients. Feb 4, 2026 - $CPIX
Zacks Initiates Coverage of CPIX With Outperform Recommendation
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates Cumberland as "Outperform." Explore how CPIX's scalable commercial model, long-duration Talicia revenues and pipeline upside create an attractive risk-reward setup for investors. Dec 19, 2025 - $CPIX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple